GO
Loading...

AstraZeneca PLC

More

  • Pfizer's bid to take over U.K. pharmaceutical company AstraZeneca would have probably "fallen apart", Pascal Soriot, the firm's CEO, told CNBC.

  • Pfizer deal would probably have failed: AZ CEO Friday, 28 Nov 2014 | 1:01 AM ET
    Viagra made by Pfizer and Nexium made by AstraZeneca.

    Pfizer's attempt to take over AstraZeneca through a $110 billion bid would have run aground on changes to U.S. tax laws, even if the companies had reached a deal.

  • Pfizer to join forces with AstraZeneca?     Wednesday, 26 Nov 2014 | 4:35 AM ET

    American pharmaceutical giant has been pursuing AstraZeneca for some time, however CNBC's Catherine Boyle says it looks like the deal has "definitely receded".

  • Back for more: Will Pfizer top its AstraZeneca bid? Wednesday, 26 Nov 2014 | 3:34 AM ET
    Viagra made by Pfizer and Nexium made by AstraZeneca.

    Pfizer’s $110 billion bid for AstraZeneca was one of the biggest business stories of 2014 – so could a new bid be one of the biggest stories in 2015?

  • Pfizer to renew pursuit of AstraZeneca?     Wednesday, 26 Nov 2014 | 1:20 AM ET

    Pfizer has seen off its six month cooling period before it can launch another bid for AstraZeneca, but will the American drugs giant continue its pursuit?

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral, a court filing showed. Ranbaxy had filed a lawsuit against the U.S. Food and Drug Administration last week for revoking tentative approvals it gave the company to make...

  • Nov 20- A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed. Ranbaxy had sought the restraining order against Dr Reddy's Laboratories and U.S. firm Endo International Plc in a lawsuit it filed...

  • European shares erase gains ahead of Fed minutes Wednesday, 19 Nov 2014 | 12:35 PM ET

    LONDON, Nov 19- European shares ended flat after hitting a seven-week high earlier on Wednesday, with investors trading cautiously ahead of minutes from the most recent Federal Reserve policy meeting. The market also faced pressure from a sharp decline in mining shares after China's iron ore futures dropped nearly 5 percent to a record low.

  • Sanofi's case for experimental drugs in pipeline Wednesday, 19 Nov 2014 | 12:24 PM ET

    After drug company Sanofi removed CEO Chris Viehbacher, investors question the future of the company's growth and future.

  • European shares edge lower ahead of Fed minutes Wednesday, 19 Nov 2014 | 11:24 AM ET

    LONDON, Nov 19- European shares edged lower from a seven-week high late on Wednesday, tracking a fall in U.S. equities, with investors trading cautiously ahead of minutes from the most recent Federal Reserve policy meeting. The market also came under pressure from a sharp decline in mining shares after China's iron ore futures dropped nearly 5 percent to a record...

  • European shares advance, Swiss index hits 9,000 Wednesday, 19 Nov 2014 | 8:48 AM ET

    LONDON, Nov 19- The pan-European FTSEurofirst 300 share index climbed to a seven-week high on Wednesday, helped by broker upgrades, and Switzerland's SMI equity index hit the 9,000 mark for the first time since late 2007.. Prudential rose 1.3 percent after Deutsche Bank increased its target price for the stock to 1,680 pence from 1,630 pence, Severn Trent was up...

  • European shares edge higher, Swiss index hits 7-year high Wednesday, 19 Nov 2014 | 6:09 AM ET

    LONDON, Nov 19- European shares turned positive in morning trading on Wednesday, helped by some encouraging broker upgrades, with Switzerland's SMI equity index hitting the 9,000- point mark for the first time since late 2007.. Prudential rose 1.1 percent to lead insurers after Deutsche Bank increased its target price for the stock to 1,680 pence from 1,630...

  • Midday movers: Allergan, Apple, Fluor & more Tuesday, 18 Nov 2014 | 12:56 PM ET

    Some of Tuesday midday movers:

  • *AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs on Tuesday, aiming to show investors it has a strong independent future just days before takeover rules would allow Pfizer to launch a new bid. AstraZeneca, which saw off a $118 billion approach from Pfizer in May, is his...

  • *AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs at an investor day on Tuesday, aiming to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May. AstraZeneca is his biggest holding.

  • AstraZeneca trumpets strength in drug development Tuesday, 18 Nov 2014 | 3:24 AM ET
    British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England.

    AstraZeneca said it had made good progress in developing a pipeline of new drugs.

  • *Investor day comes 8 days before Pfizer can resume pursuit. LONDON, Nov 18- AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs. It reiterated it was on course to return to growth and that annual sales would rise by three quarters...

  • AstraZeneca trumpets progress in cancer, other drugs Tuesday, 18 Nov 2014 | 2:20 AM ET

    LONDON, Nov 18- AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs. AstraZeneca executives will present further details at a six-hour investor meeting later on Tuesday. The event comes just eight days before British takeover...

  • Early Movers: BHI, HAL, TSN, AGN, GM, MAR & more Monday, 17 Nov 2014 | 8:14 AM ET

    Some of the names on the move ahead of the open.

  • LONDON, Nov 17- An experimental lupus drug from AstraZeneca significantly improved the symptoms of lupus in a mid-stage clinical trial, boosting prospects for a medicine the company believes could become a major seller. AstraZeneca's sifalimumab works in a different way to Benlysta by targeting interferon, a protein involved in inflammation.